Two lawsuits represent two sides of genetic testing, the Economist writes: to know or not your risk of developing disease.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.
NPR reports on a clinical trial examining an antisense oligonucleotide drug for Huntington's disease.
The test will run on Oxford Nanopore's MinIon and will be used as a reflex test when the standard PCR test does not give a clear answer.
The researchers studied edits generated by more than 40,000 gRNAs and gathered data for more than 109 mutational outcomes to create the software.
A UK woman sues a hospital for not telling her of her father's genetic testing results, the Guardian reports.
In Science this week: molecular drivers of small cell neuroendocrine carcinomas, and more.
In PLOS this week: Huntington's disease modifiers, possible new Chikungunya virus subgroup, and more.
Six microRNAs appeared to be present at enhanced levels in cerebrospinal fluid from symptom-free individuals with characteristic Huntington disease gene expansions.
According to Slate, some people prefer not to know their genetic risk of certain diseases.
Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.
University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.
NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.
In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.